Table 1.
Characteristics of the 27 included studies.
| Study (years) | Diagnostic criteria | Number of participants (male/female), mean age (years) | Interventions | Conventional medicine or basic treatment | Duration of treatment | Outcome index | Intergroup differences | ||
|---|---|---|---|---|---|---|---|---|---|
| Trial | Control | Trial | Control | ||||||
| Lu et al., 2006 | After PCI | 60 58.94 ± 10.79 |
58 57.1 ± 9.81 |
Xiongshao capsule (0.5g, tid, p.o). | Placebo | Clopidogrel, aspirin; atorvastatin, low molecular weight heparin | 6 months | 1. Cardiovascular mortality 2. The rate of coronary restenosis 3. The degree of coronary artery stenosis 4. The efficiency of angina pectoris 5. Myocardial infarction rate 6. The incidence of PCI |
1. P < 0.05 2. P < 0.05 3. P < 0.05 4. P < 0.05 5. P < 0.05 6. P < 0.05 |
| Qiao et al., 2006 | After PCI | 30 (17/13) 64.0 ± 11.2 |
29 (18/11) 65.7 ± 12.2 |
Tongguan capsule (three doses, tid, p.o). | Placebo | Anticoagulant, antiplatelet, anti-infection | 1 month | 1. LVEF 2. The ventricular wall motion score 3. Survey of angina pectoris in Seattle |
1. P < 0.05 2. P < 0.05 3. P < 0.05 |
| Lu et al., 2008 | Documented previous myocardial infarction | 2,429 58.35 ± 9.02 |
2,441 58.35 ± 9.02 |
Xuezhikang capsule (0.6g, bid, p.o). | Placebo | Other drugs that do not affect blood lipids | 4.5 years | 1. Myocardial infarction rate 2. Cardiovascular mortality 3. The incidence of PCI 4. TC 5. TG 6. HDL-C 7. LDL-C |
1. P < 0.05 2. P < 0.05 3. P < 0.05 4. P < 0.01 5. P < 0.01 6. P < 0.01 7. P < 0.01 |
| Cheng et al., 2009 | The guideline of chronic stable angina from China, 2007 | 41 (37/4) 49.97 ± 6.19 |
41 (39/2) 51.12 ± 7.33 |
Qingre Quyu granule (6g, bid, p.o). | Placebo | Aspirin, bisoprolol fumarate, isosorbide dinitrate sustained release tablets | 25 weeks | 1. Number of atherosclerotic plaques 2. Arterial plaque score 3. Intima thickness of carotid artery 4. hsCRP |
1. P < 0.05 2. P < 0.05 3. P < 0.05 4. P < 0.05 |
| Qiu et al., 2009 | The guideline of acute myocardial infarction from China, 2001 | 51 (45/6) 57.82 ± 10.23 |
52 (44/8) 55.79 ± 11.06 |
Compound Salvia tablet and Xinyue capsule | Placebo | Antiplatelet agents, anticoagulant, β blocker, angiotensin converting enzyme inhibitor, nitrates, and lipid-regulating drugs | 3 months | 1. LVEF | 1. P < 0.05 |
| Wang et al., 2009 | The guideline of unstable angina pectoris from ACC/AHA USA, 2002 | 32 (12/20) 61.65 ± 8.15 |
31 (13/18) 64.47 ± 9.21 |
Shenshao tablet (0.3g, qd, p.o). | Placebo | Aspirin, isosorbide, mononitrate, simvastatin, Benner Pury, amlodipine, metoprolol |
4 weeks | 1. Frequency of angina pectoris 2. Seattle score 3. The incidence of PCI 4. Acute myocardial infarction rate |
1. P < 0.05 2. P < 0.05 3. P > 0.05 4. P > 0.05 |
| Chu et al., 2010 | After PCI | 28 (18/10); 61.7 ± 9.6 |
29 (20/9); 58.8 ± 8.9 |
Xuefu Zhuyu capsule | Placebo | Clopidogrel, aspirin, low molecular weight heparin, metoprolol tartrate, atorvastatin | 4 weeks | 1. The efficiency of angina pectoris 2. Electrocardiogram curative effect 3. Survey of angina pectoris in Seattle |
1. P < 0.05 2. P < 0.05 3. P < 0.05 |
| Zhang et al., 2010 | The guideline of segment elevation myocardial infarction from WHO | 108 (92/16) 58.5 ± 10.6 |
111 (96/15) 57.6 ± 11.2 |
Tongxinluo (2.08g, qd, p.o). | Placebo | Aspirin, clopidogrel | 180 days | 1. The incidence of no reflow of myocardium | 1. P = 0.0031 |
| Shang et al., 2011 | The guideline of stable angina pectoris from WHO | 73 (50/23) 67.79 ± 4.77 |
79 (52/27) 66.7 ± 4.16 |
Chuangxiongol (250mg, tid, p.o). | Placebo | Aspirin, tilopidine, diltiazem, nitroglycerin, heparin | 6 months | 1. Restenosis rate 2. The efficiency of angina pectoris 3. Cardiovascular mortality 4. Acute myocardial infarction rate 5. The incidence of PCI |
1. P > 0.05 2. P < 0.01 3. P > 0.05 4. P > 0.05 5. P > 0.05 |
| Mo et al., 2012 | The guideline of criteria for the naming and diagnosis of ischemic heart disease | 60 (43/17) 67.15 ± 4.87 |
60 (42/18) 66.22 ± 5.12 |
Yixin Mai granule (one dose, tid, p.o). | Placebo | Isosorbide, metoprolol, fosinopril, aspirin | 4 weeks | 1. hsCRP 2. IL-6 3. IL-18 4. The efficiency of angina pectoris |
1. P < 0.01 2. P < 0.01 3. P < 0.01 4. P = 0.037 |
| Wang S. H. et al., 2012 | The guideline of unstable angina pectoris from ACC/AHA USA, 2002 | 33 (26/7) 60.2 ± 9 |
33 (25/8) 62.7 ± 7.1 |
Tablets of betel (1.5g, bid, p.o). | Placebo | Aspirin, simvastatin, isosorbide, dinitrate | 28 days | 1. The efficiency of angina pectoris 2. Electrocardiogram efficiency 3. Nitroglycerin consumption 4. hsCRP 5. sCD40L |
1. P < 0.05 2. P > 0.05 3. P < 0.05 4. P < 0.05 5. P < 0.05 |
| Wang Y. G. et al., 2012 | The guideline of chronic stable angina from China, 2007 | 76 | 72 | Double ginseng capsule and Tongguan capsule (four doses, tid, p.o). | Placebo | Original treatment | 6 months | 1. TG 2. TC 3. HDL-C 4. LDL-C |
1. P < 0.05 2. P > 0.05 3. P < 0.05 4. P < 0.05 |
| Chen et al., 2013 | After PCI | 30 (17/13) 65.5 ± 7.5 |
30 (16/14) 63.8 ± 6.3 |
Tongguan capsule (three doses, tid, p.o). | Placebo | Clopidogrel, aspirin, low molecular weight heparin | 3 months | 1. LVEF 2. The ventricular wall motion score 3. The number of endothelial progenitor cell in peripheral blood |
1. P < 0.05 2. P < 0.05 3. P < 0.05 |
| Shang et al., 2013 | The guideline of chronic stable angina from China, 2004 | 1,746 (1,191/555) 58.35 ± 9.02 |
1,759 (1,260/499) 58.28 ± 8.99 |
QSYQ (0.5g, tid, p.o). | Placebo | Antihypertensive drugs, hypoglycemic agent, lipid-lowering medicine | 12 months | 1. Cardiovascular mortality 2. Myocardial infarction rate 3. The incidence of PCI |
1. P > 0.05 2. P > 0.05 3. P > 0.05 |
| Hu et al., 2014 | The guideline of chronic stable angina from China, 2007 | 192 57.82 ± 10.23 |
99 57.82 ± 10.23 |
Reachable film (three doses, tid, p.o). | Placebo | NM | 4 weeks | 1. The efficiency of angina pectoris 2. The total curative effect of TCM Syndrome 3. Electrocardiogram efficiency |
1. P < 0.05 2. P < 0.05 3. P < 0.05 |
| Liu et al., 2014 | The guideline of chronic stable angina from China, 2007 | 120 59.21 ± 7.92 |
120 60.64 ± 7. 69 |
Chek Shincen Tongxin granule | Placebo | Aspirin, atorvastatin | 4 weeks | 1. Body limitation 2. Stable state of angina pectoris 3. Episodes of angina pectoris 4. Satisfaction with treatment 5. The degree of understanding of disease 6. Electrocardiogram efficiency |
1. P < 0.05 2. P < 0.05 3. P < 0.05 4. P < 0.05 5. P < 0.05 6. P < 0.05 |
| Lu et al., 2014 | After PCI | 90 (48/42) 60.2 ± 6.9 |
90 (46/44) 61.8 ± 7.2 |
Tongxinluo capsule (three doses, tid, p.o). | Placebo | Original treatment | 12 months | 1. The incidence of coronary restenosis 2. The degree of coronary restenosis 3. The efficiency of angina pectoris 4. Myocardial infarction rate 5. Cardiovascular mortality |
1. P < 0.05 2. P < 0.01 3. P = 0.04 4. P = 0.19 5. P > 0.05 |
| Sun, 2014 | The guideline of chronic unstable angina from China, 2007 | 64 (42/22) 70.81 ± 10.76 |
64 (44/20) 69.8 ± 10.98 |
Musk Baoxin pill (two doses, tid, p.o). | Placebo | Isosorbide dinitrate tablets, atorvastatin, thiazepine, enteric aspirin | 6 months | 1. The efficiency of angina pectoris 2. Myocardial infarction rate 3. Cardiovascular mortality 4. Nitroglycerin consumption 5. Electrocardiogram efficiency 6. LVEF |
1. P < 0.05 2. P < 0.05 3. P > 0.05 4. P < 0.01 5. P < 0.05 6. P < 0.05 |
| Xu et al., 2014 | The guideline of unstable angina pectoris from ACC/AHA USA, 2002 | 55 (29/26) 69.47 ± 8 |
59 (33/26) 70.41 ± 8.6 |
Shenzhu Guanxin recipe (12g, qd, p.o). | Placebo | Conventional western medicine (unspecified) | 12 weeks | 1. The efficiency of angina pectoris 2. The duration of angina pectoris 3. Total use of nitroglycerin 4. The degree of physical activity induced by angina pectoris 5. The degree of angina pectoris |
1. P < 0.05 2. P < 0.05 3. P < 0.05 4. P < 0.05 5. P < 0.01 |
| Xu et al., 2015 | After PCI | 113 (86/27) 70.35 ± 9.61 |
74 (51/23) 68.08 ± 10.38 |
Shenzhu Guanxin recipe | Placebo | Aspirin, ticplopidine, diltiazem, glyceryl, trinitrate, heparin | 3 months | 1. Angina pectoris score 2. Cardiovascular mortality 3. Myocardial ischemia rate |
1. P = 0.66 2. P = 0.33 3. P = 0.63 |
| Zhang et al., 2015 | The guideline of unstable angina pectoris from ACC/AHA USA, 2002 | 119 (56/63) 59.46 ± 6.524 |
120 (52/68) 58.82 ± 7.061 |
Wufuxinnaoqing capsules | Placebo | Antiplatelet, aggregation, ACEI or ARB, statin two hydrogen arsenide | 12 weeks | 1. The efficiency of angina pectoris 2. Nitroglycerin consumption |
1. P < 0.01 2. P < 0.01 |
| Duan et al., 2016 | The guideline of chronic stable angina from China, 2007 | 64 (38/26) 59.7 ± 6.34 |
67 (47/20) 60.7 ± 6.44 |
Live heart pill (two doses, tid, p.o). | Placebo | Conventional western medicine (unspecified) | 8 weeks | 1. Symptom score of angina pectoris 2. Nitroglycerin consumption 3. Electrocardiogram plate movement 4. Seattle scale 5. Syndromes of traditional Chinese Medicine 6. hsCRP 7. Blood lipid |
1. P < 0.01 2. P < 0.01 3. P < 0.01 4. P < 0.01 5. P < 0.01 6. P > 0.05 7. P > 0.05 |
| Mao et al., 2016 | After PCI | 42 67.54 ± 8.39 |
41 68.38 ± 10.41 |
Danlou tablet | Placebo | Conventional western medicine (unspecified) | 90 days | 1. Left ventricular end diastolic volume index 2. End systolic volume index of left ventricle 3. LVEF 4. Cardiovascular mortality 5. Myocardial infarction rate |
1. P < 0.001 2. P < 0.001 3. P < 0.001 4. P < 0.05 5. P < 0.05 |
| Wang et al., 2016 | The guideline of unstable angina pectoris from ACCF/AHA USA, 2007 | 109 (72/37) 62.89 ± 9.23 |
110 (74/36) 63.89 ± 10.03 |
Danlou tablet (4.5g, qd, p.o). | Placebo | Antiplatelet, aggregation, anticoagulant, lipid-lowering, improvement of myocardial, remodeling, step-down | 90 days | 1. Cardiovascular mortality 2. Myocardial infarction rate 3. Reconstructive rate of blood vessels 4. Troponin 5. hsCRP |
1. P > 0.05 2. P = 0.04 3. P > 0.05 4. P > 0.05 5. P > 0.05 |
| Zhu et al., 2016 | The guideline of chronic stable angina from China, 2007 | 76 (48/28) 51.8 ± 1.6 |
74 (46/28) 51. 5 ± 1. 4 |
Traditional Chinese medicine prescription (10 mg, tid, p.o). | Placebo | Isosorbide, aspirin, atorvastatin | 4 weeks | 1. The efficiency of angina pectoris 2. Electrocardiogram efficiency 3. TG 4. TC 5. HDL-C 6. LDL-C 7. TCM syndrome score |
1. P < 0.05 2. P < 0.05 3. P < 0.05 4. P < 0.05 5. P < 0.05 6. P < 0.05 7. P < 0.05 |
| Wang et al., 2017 | The guideline of unstable angina pectoris from ACC/AHA USA, 2011 | 40 (17/23) 70.68 ± 6.87 |
40 (21/19) 71.65 ± 4.32 |
Xuesaitong soft capsule (0.66g, bid, p.o). | Placebo | Conventional western medicine (unspecified) | 4 weeks | 1. TC 2. TG 3. HDL 4. LDL 5. Survey of angina pectoris in Seattle |
1. P < 0.05 2. P < 0.05 3. P < 0.05 4. P < 0.05 5. P < 0.05 |
| Yang et al., 2017 | The guideline of chronic stable angina from China, 2014 | 33 (20/13) 61.18 ± 6.61 |
33 (21/12) 61.03 ± 7.51 |
Coronary Ningtong prescription | Placebo | Aspirin enteric-coated tablets, simvastatin tablets, isosorbide mononitrate, metoprolol | 24 weeks | 1. Coronary stenosis 2. The efficiency of angina pectoris |
1. P < 0.05 2. P < 0.05 |
PCI, percutaneous coronary intervention; LVEF, left ventricular ejection fraction; hsCRP, high sensitive C reactive protein; TC, total cholesterol; TG, total glycerol three fat; HDL, high density lipoprotein; LDL, low density lipoprotein; STEMI, segment elevation myocardial infarction; WHO, world health organization; NM, not mention; QSYQ, Qi-Shen-Yi-Qi dripping pills.